GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity

GLP-1 Drugs for Obesity and Weight Loss

GLP-1 Drugs for Obesity and Weight Loss
iStock; Everyday Health

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments.

Glucagon-like peptide-1 (GLP-1) agonists are injectable weight loss drugs that help people feel fuller and eat less food, leading to weight loss. The drugs also boast other health benefits, such as protection against cardiovascular disease.

What Are GLP-1 Drugs?

GLP-1 receptor agonists, sometimes simply called GLP-1s, were originally developed to manage the blood sugar levels of people with type 2 diabetes. Researchers later learned that GLP-1 drugs could also cause dramatic weight loss in people who do not have diabetes.

The U.S. Food and Drug Administration (FDA) has approved four GLP-1 drugs for weight loss in people with overweight or obesity:

  • liraglutide (Saxenda)
  • orforglipron (Foundayo)
  • semaglutide (Wegovy)
  • tirzepatide (Zepound)
Tirzepatide, though generally grouped with semaglutide and other GLP-1 drugs, is technically a GIP/GLP-1 drug because it mimics both GLP-1 and GIP, a second digestive hormone.

(One of the review’s authors has received funding from pharmaceutical companies, including those that make GLP-1 medications.)

Liraglutide, semaglutide, and tirzepatide are injectable medications that come in prefilled pens. Once per day or per week, users attach a needle to their pen, prick themselves in the torso or another fleshy area, and press a button on the pen to administer their medication.

Orforglipron comes only as a pill, which can be taken at any time of day without restrictions. An oral version of semaglutide is also available. Users take this pill in the morning on an empty stomach and wait half an hour before eating or drinking.

Doctors start their patients on lower “starter” doses and work their way up — it can take months to work up to a full-strength dosage.

Each of these drugs is also marketed under a different name for the treatment of diabetes: semaglutide (Ozempic), tirzepatide (Mounjaro), and liraglutide (Victoza). This may cause some confusion: Though Ozempic and Wegovy, for example, come in different packages and in different doses, they are in fact the same drug.

How GLP-1 Drugs Promote Weight Loss

GLP-1 drugs mimic a hormone named GLP-1 that our bodies naturally produce during and after meals. This hormone plays several important roles in regulating our hunger and metabolic health. GLP-1:

  • Signals a feeling of being full
  • Slows down digestion
  • Regulates the release of insulin from the pancreas
GLP-1 drugs also act directly on the brain. Many users report that they suddenly have fewer intrusive thoughts about food, or food noise. GLP-1s may also help people naturally crave healthier food, by reducing preference for fatty, high-calorie foods, according to landmark research that was funded in part by Novo Nordisk (drugmaker of Wegovy).

In a nutshell, GLP-1 drugs allow people to eat less without feeling hungrier than normal. Some users can happily eat as much as they want and will still lose a substantial amount of weight.

Who Is Eligible to Use GLP-1 Drugs for Weight Loss?

Wegovy, Zepbound, Saxenda, and Foundayo are all approved as weight loss medications for the following people with a demonstrated medical need to lose weight.

Wegovy and Saxenda are also approved for the treatment of children age 12 and older; the precise BMI cutoffs for children differ by age.

Only your healthcare team can decide which of these drugs, if any, will work best for you.

How Much Weight Will I Lose?

Not everybody responds equally well to these treatments, and it’s impossible to predict how effective any specific weight loss medication will be for you. The results of major clinical trials suggest how much weight the average user may expect to lose.

One large meta-analysis of 14 systematic reviews looked at the weight loss outcomes of six drugs (including semaglutide, liraglutide, and tirzepatide) measured at six months, 12 months, and beyond one year. After six months, tirzepatide injections were the most effective, with participants losing an average of 19.8 pounds on a dose of 5 milligrams (mg), and 26.5 pounds (lb) on a 15-mg dose. Overall, 2.4-mg semaglutide injections yielded the biggest results, with participants losing an average of 25.3 to 27.6 lb.

Liraglutide didn’t achieve quite the same level of weight loss. On average, users taking a 3-mg dose lost 11 lb. after the first year. The average weight loss decreased to 7.5 lb., according to results extending beyond 12 months.

But some people won’t see these results. About 23 percent of Wegovy users lost less than 5 percent of their body weight.

This ranges between 17 and 21 percent for Zepbound users (based on research funded by its drugmaker).

Additionally, a minority of users will find it necessary to discontinue the drug because they cannot tolerate the side effects, which are mostly gastrointestinal issues such as vomiting and nausea. Tirzepatide has the highest discontinuation rate, with participants being 6 to 8.5 times more likely to stop using it in comparison to a placebo. In comparison, liraglutide has a 3.8 times risk of discontinuation, and semaglutide’s rate ranges between 1.7 and 4.55

GLP-1 weight loss also seems to do an especially good job of targeting the loss of fat in the abdomen, sometimes called visceral fat.

This fat, which squeezes around the vital organs, is considered much more dangerous than the fat found elsewhere on the body.

It’s important to emphasize that GLP-1 weight loss drugs are meant to be used in tandem with regular exercise and a healthy diet. The weight loss reported in the above studies all occurred in volunteers who were also asked to maintain healthy eating and exercise habits.

Illustrative graphic titled The Benefits of GLP-1 Drugs for Obesity shows weight loss, lower blood pressure, reduced, less visceral fat, kidney health protection, heart health protection, lower cholesterol, lower blood sugar, less inflammation. EH
GLP-1 drugs have many benefits beyond weight loss.Everyday Health

Additional GLP-1 Benefits

GLP-1s have health benefits that extend beyond weight loss.

Heart Health Protection

When people who are overweight use GLP-1 medications, they tend to experience broad cardiovascular and metabolic health improvements, depending on the medication. Benefits can include:

Long-term cardiovascular outcome studies show liraglutide and semaglutide can significantly reduce the risk of heart attack, stroke, or early death from cardiovascular conditions.

Semaglutide can now be prescribed for people who are overweight or have obesity specifically to reduce the risk of dying early from cardiovascular disease.

Tirzepatide and orforglipron are newer drugs that don’t yet have results from long-term cardiovascular health trials.

Secondary Benefits

GLP-1 drugs also appear to have some extra benefits.

  • Zepbound is also an FDA-approved treatment for moderate to severe obstructive sleep apnea (OSA).

  • GLP-1 drugs have anti-inflammatory properties that may benefit those with asthma and chronic obstructive pulmonary disease (COPD).

  • GLP-1 drugs also seem to have anti-addictive properties — some users report that they have fewer cravings for alcohol or have become less likely to engage in other addictive behaviors, such as gambling, shopping, or nail-biting. Researchers are now studying semaglutide and similar drugs for their anti-addiction effects.
  • Preliminary studies have suggested that GLP-1 drugs might protect against or treat dementia and Alzheimer’s disease.

GLP-1 Drug Risks and Side Effects

GLP-1 drugs are associated with a wide variety of side effects.

Common Side Effects

Gastrointestinal distress is the most common side effect reported by people who take GLP-1s, and is experienced by a high percentage of users. This includes nausea, diarrhea, constipation, vomiting, and abdominal pain.

In the majority of people in clinical trials, these side effects have been mild or moderate. Gastrointestinal issues are usually strongest in first-time users, or when people step up to a larger dosage, but they usually dissipate over time. A small number of users may experience gastrointestinal effects so severe that they need to stop taking the medication.

Rare, More Serious Side Effects

Other side effects are much more rare, but potentially serious. GLP-1 agonists can cause inflammation of the pancreas, called pancreatitis, bowel obstruction, and gastroparesis (paralysis of the stomach).

In people who are allergic or hypersensitive to GLP-1s, the drug can cause anaphylaxis, a dangerous reaction that can involve the rapid onset of hives, swelling, and even loss of consciousness.

GLP-1 drugs can also create a risk of hypoglycemia, or dangerously low blood sugar, in people who use certain type 2 diabetes drugs, chiefly insulin and sulfonylureas.

Anecdotal Side Effects

There has also been plenty of media buzz about anecdotal side effects with names like “Ozempic face” and “Ozempic butt.”

These cosmetic side effects aren’t unhealthy, and aren’t directly caused by GLP-1s. Instead, they are caused by rapid, significant weight loss.

Weight loss can make parts of your body look different. While your belly may slim down, so might your buttocks and face. In some people, weight loss can lead to looser or sagging skin. Weight loss can also cause hair loss, and may be responsible for other rarely reported side effects, such as tiredness.

Warnings

GLP-1 drugs are powerful medications that may not be appropriate for everybody.

GLP-1s may be risky for older adults. Significant weight loss isn’t always a benefit for older adults, especially if it means the loss of bone and muscle mass, which are critical for good physical health. It’s possible to reduce the risks by eating enough protein and engaging in strength-building exercises, such as weight lifting.

People who should not use GLP-1s include:

  • Pregnant people
  • People with a personal or family history of medullary thyroid cancer
  • People with multiple endocrine neoplasia syndrome type 2, a rare condition that affects the endocrine glands
  • People who are hypersensitive to GLP-1 agonist drugs

GLP-1 Drugs Are Lifelong Treatments

Experts say that you need to keep taking GLP-1 drugs if you want to continue to enjoy the benefits. When you stop taking a GLP-1 agonist, you will probably regain some or all of the weight you lost.

Your hunger and “food noise” may return to previous levels.
One meta-analysis found that regardless of lifestyle interventions, stopping GLP-1 medication causes users to regain weight in proportion to how much weight they lost. On average, those who were taking semaglutide or tirzepatide regained 21.3 lb (on average) after they stopped taking the medication, while liraglutide users regained an average of 4.9 lb.

Healthy diet and exercise habits can also help maximize the benefits of GLP-1 drugs. Nutrition is still crucial, as getting the right amount of protein, fiber, nutrients, and hydration is more difficult when you’ve drastically cut your food intake.

And exercising can enhance the health benefits and prevent some of the bone density loss that usually occurs during weight loss.

If you establish healthy diet and exercise habits while using a GLP-1, it will be easier to maintain some weight loss if you have to stop taking the medication.

Questions to Ask Your Doctor

  • Am I a candidate for a GLP-1 weight loss drug?
  • What kind of weight loss can I expect?
  • Do I have additional obesity-related health conditions, like elevated cardiovascular risks?
  • How can I prepare for side effects like nausea?
  • How long should I expect to be on the medication before seeing results?
  • How should I change my diet and exercise plans while taking the medication?
  • Are compounded GLP-1 drugs safe?

Cost, Insurance Coverage, and Access

Public insurance coverage for GLP-1 obesity treatments is spotty in the United States.

Only a minority of state Medicaid boards have chosen to cover GLP-1 drugs when prescribed as an obesity treatment, and coverage in ACA Marketplace plans is limited.

Medicare doesn’t cover obesity treatments, though it is possible to have Wegovy, Ozempic, or Mounjaro approved and reimbursed if it has been prescribed for cardiovascular disease or type 2 diabetes.

Private insurers vary widely in their coverage. Most large employers do not offer GLP-1 coverage for weight loss, though this is changing. According to KFF’s 2025 Employer Health Survey of more than 1,800 firms, 19 percent of companies with 200 or more employees have at least one plan that covers GLP-1 drugs.

Some insurers, faced with staggering costs due to the huge number of claims for GLP-1 drugs, have tightened or revoked their coverage.

Many users are left to pay for GLP-1 weight loss medications, which can cost more than $1,000 per month, out of pocket.

The high price of GLP-1s has created a market for less-expensive compounded versions of the drugs. These off-brand equivalents are mixed in a private compounding pharmacy and are not subjected to rigorous FDA testing. Many doctors endorse and prescribe compounded GLP-1 weight loss drugs. However, others warn explicitly against their use, including the FDA and many clinicians, naming concerns over safety, quality, and effectiveness, and calling out often lax prescribing policies and misleading marketing claims by the websites that sell them.

It is unclear how long compounded GLP-1 drugs will remain available: GLP-1 manufacturers are arguing to restrict the sale of compounded weight loss drugs, and the compounding pharmacies are pushing back.

Alternatives to GLP-1 Drugs

GLP-1 agonists are not the only option for weight loss.

It may go without saying, but the old-fashioned way — diet and exercise — remains a preferred weight loss method. Indeed, many doctors require people to try diet and exercise alone before trying GLP-1s. Different eating patterns and exercise regimens work for different people, and it’s best to work with a doctor or dietitian if you can. Low-carb and Mediterranean diets are both popular and research-backed ways of eating that can help people lose excess fat. A combination of cardio exercises and strength training is often the best exercise strategy for weight loss.

If you cannot access or afford newer GLP-1 medications, a generation of older weight loss drugs is still available. Though these drugs are generally less effective than newer alternatives, they can work for many people:

  • Orlistat (Alli, Xenical) reduces the amount of fat absorbed by the intestines.
  • Phentermine-topiramate (Qsymia) suppresses appetite and helps people eat less.
  • Bupropion-naltrexone (Contrave) reduces hunger signals in the brain.

Weight loss surgery, or bariatric surgery, is also an option for some people with a need to lose weight. The benefits are comparable or superior to the benefits of GLP-1 drugs, including dramatic weight loss and secondary long-term health benefits, such as improved blood sugar levels. Weight loss surgery may seem intense and expensive, but it is often covered by insurers, and the out-of-pocket cost could be far less than years of GLP-1 therapy.

FAQ

Who can take GLP-1 drugs for weight loss?

Wegovy, Zepbound, Saxenda, and Foundayo are approved to treat adults with a BMI of 30 or greater, or with a BMI of at least 27 and one weight-related condition, such as high blood pressure or high cholesterol.

How much weight a person loses on GLP-1 agonists depends on many factors, including genetics and how they respond to the drugs. One review found that users lost an average of 25.3 to 27.6 lb.

Almost certainly, yes, you will gain back some of the weight you lost. Users of semaglutide or tirzepatide tend to gain back the most weight, regaining an average of 21.3 lb after stopping the medication.

These drugs should not be used by pregnant people, people with a personal or family history of thyroid cancer, or people with multiple endocrine neoplasia syndrome type 2.

Dive into our GLP-1 resource center for stories on weight loss, medications, side effects, and more.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Vosoughi K et al. Effects of GLP-1 Agonists on Proportion of Weight Loss in Obesity With or Without Diabetes: Systematic Review and Meta-Analysis. Obesity Medicine. October 1, 2022.
  2. Hammoud R et al. Beyond the Pancreas: Contrasting Cardiometabolic Actions of GIP and GLP1. Nature Reviews Endocrinology. December 12, 2022.
  3. Blundell J et al. Effects of Once‐weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity. Diabetes, Obesity & Metabolism. May 5, 2017.
  4. Considering GLP-1 Medications? What They Are and Why Lifestyle Change is Key to Sustained Weight Loss. Mayo Clinic. August 22, 2023.
  5. Nunns M et al. The Quantity, Quality and Findings of Network Meta-Analyses Evaluating the Effectiveness of GLP-1 RAs for Weight Loss: A Scoping Review. National Institute for Health and Care Research. June 25, 2025.
  6. Garvey WT et al. Lancet Title: Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (Surmount-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet. August 19, 2023.
  7. Lu J et al. The Effects of GLP-1 Receptor Agonists on Body Composition in Patients With Type 2 Diabetes, Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials. European Journal of Pharmacology. September 15, 2025.
  8. Taking Aim at Belly Fat. Harvard Health Publishing. March 26, 2024.
  9. Kennedy C et al. Semaglutide and Blood Pressure: An Individual Patient Data Meta-Analysis. European Heart Journal. October 7, 2024.
  10. Gul U et al. A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure. Cureus. December 28, 2024.
  11. Park MJ et al. Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Thiazolidinediones on Treating Nonalcoholic Fatty Liver Disease: A Network Meta-Analysis. Clinical and Molecular Hepatology. March 9, 2023.
  12. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs). American Kidney Fund. February 12, 2024.
  13. Hamed K et al. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review. Cureus. September 1, 2024.
  14. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration. March 8, 2024.
  15. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. December 20, 2024.
  16. Yang K et al. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes. JAMA Network Open. March 31, 2026.
  17. Guo H et al. Comparative Efficacy and Safety of GLP-1 Receptor Agonists for Weight Reduction: A Model-Based Meta-Analysis of Placebo-Controlled Trials. Obesity Pillars. January 30, 2025.
  18. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. October 5, 2023.
  19. Anthony MS et al. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study. Diabetes Care. February 16, 2024.
  20. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
  21. Jia IT et al. Analysis of the Long-Term Impact of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Control of Obesity and Obesity-Related Comorbidities: A Meta-Analysis. Surgical Endoscopy. December 2025.
  22. Berg S et al. Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis. Obesity Reviews. April 4, 2025.
  23. Balch B. GLP-1 Pills for Weight Loss are Here. How Will They Change Obesity Care? Association of American Medical Colleges. March 5, 2026.
  24. Munoz-Mantilla D. Top Weight Loss Medications. Obesity Medicine Association. April 2, 2026.
  25. Williams E. Medicaid Coverage of and Spending on GLP-1s. KFF. January 16, 2026.
  26. Wreschnig LA. Medicare Coverage of GLP-1 Drugs. Library of Congress. September 9, 2024.
  27. 2025 Employer Health Benefits Survey. KFF. October 22, 2025.
  28. Beasley D. Focus: US Diabetes Patients Face Delays as Insurers Tighten Ozempic Coverage. Reuters. December 13, 2023.
  29. Chetty AK et al. Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation. Journal of General Internal Medicine. July 22, 2025.
Sean-Hashmi-bio

Sean Hashmi, MD

Medical Reviewer

Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management ...

Kaitlin Sullivan

Kaitlin Sullivan

Author
Kaitlin Sullivan reports on health, science, and the environment from Colorado. She has a master's in health and science journalism from the City University of New York.